Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug
Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy.
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting disappointing late-stage trial data.
Novo Nordisk's new weight-loss drug works better, but not as well as expected
Novo Nordisk's stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
On Friday, Novo Nordisk A/S NVO stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.
Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending its shares down sharply.
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare sight-threatening eye condition.
Novo Nordisk plans $1.2bn Danish factory investment
Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, plans to invest $1.2 billion in a new production facility in Odense, Denmark, focused on treatments for rare diseases. In an announcement, the company said the site will feature both a factory and a warehouse, designed to be modular and adaptable to support various rare disease products, including treatments for haemophilia.
